# SOCS3

## Overview
SOCS3, or Suppressor of Cytokine Signaling 3, is a gene that encodes a protein crucial for the negative regulation of cytokine signaling pathways, particularly the JAK-STAT pathway. The SOCS3 protein functions primarily as a cytokine-inducible negative regulator of cytokine signaling, playing a pivotal role in controlling the immune response and maintaining immune homeostasis. Structurally, the SOCS3 protein comprises several domains including a SH2 domain for binding to phosphorylated tyrosines on target receptors and a SOCS box that interacts with the E3 ubiquitin ligase complex, facilitating the degradation of signaling proteins. This regulatory mechanism is essential for preventing excessive inflammatory responses and maintaining the balance of immune cell functions (Babon2006The; Carow2014SOCS3).

## Structure
The molecular structure of the SOCS3 protein is characterized by several distinct domains and structural features that are crucial for its function in cytokine signaling inhibition. The protein includes a small N-terminal domain, a central SH2 domain, and a C-terminal SOCS box. The SH2 domain is extended by additional residues, forming an extended SH2 subdomain (ESS) that enhances its specificity and function. This domain is known for its interaction with phosphorylated tyrosines on receptor subunits such as the IL-6 signaling subunit gp130, facilitated by hydrophobic interactions and a high binding affinity (Babon2006The).

The SH2 domain contains a 35 amino acid PEST motif insertion, which is unstructured and does not contribute to phosphotyrosine binding but is significant for regulating the protein's stability by affecting its turnover (Babon2006The; Babon2005Secondary). Additionally, the SOCS box at the C-terminal interacts with the E3-ubiquitin ligase complex, facilitating the proteasome-mediated degradation of bound signaling molecules, a key aspect of SOCS3's function in the negative regulation of cytokine signaling (Babon2008The).

The secondary structure of SOCS3 includes alpha helices and beta strands, with the SH2 domain exhibiting a canonical architecture of a central four-stranded beta sheet flanked by two alpha helices. An N-terminal extension forms an additional alpha helix that interacts with parts of the SH2 domain, enhancing its phosphopeptide binding capabilities (Bergamin2006Structural). This detailed interaction and structural adaptation confer high specificity to the SOCS3 SH2-phosphopeptide interaction, crucial for its role in cytokine signaling inhibition.

## Function
SOCS3 (Suppressor of Cytokine Signaling 3) is a critical regulator of cytokine signaling pathways, particularly the JAK-STAT pathway, which is pivotal for immune response modulation in healthy human cells. The protein functions by binding to JAK kinases and cytokine receptors, leading to the inhibition of STAT3 activation, thereby controlling the immune response and maintaining immune homeostasis (Carow2014SOCS3). SOCS3 is also involved in the proteasomal degradation of signaling components through its SOCS box domain, which further regulates cytokine signaling (Carow2014SOCS3).

In the context of immune cell function, SOCS3 plays a significant role in regulating the differentiation and function of T cells. It inhibits IL-23-mediated STAT3 phosphorylation, crucial for the activation of genes involved in the inflammatory response, thereby controlling the differentiation of Th17 cells and the production of IL-17, a key cytokine in inflammatory responses (Chen2006Selective). Additionally, SOCS3 is expressed in various tissues and cells, including macrophages, dendritic cells, and endothelial cells, where it inhibits the activation of focal adhesion kinase, affecting cell adhesion and motility crucial for immune cell functioning (White2011Suppressor).

Overall, SOCS3's ability to modulate cytokine signaling pathways ensures the proper development of immune cell populations and prevents excessive inflammatory responses, thereby contributing to immune homeostasis and preventing inflammatory diseases.

## Clinical Significance
SOCS3 mutations and alterations in its expression are implicated in a range of diseases, highlighting its clinical significance. In breast carcinoma, reduced expression of SOCS3 is associated with aggressive tumor characteristics and poor prognosis, suggesting its role as a potential tumor suppressor gene (Ying2010Loss). Similarly, hypermethylation of the SOCS3 promoter, leading to decreased expression, has been observed in myeloproliferative disorders, particularly idiopathic myelofibrosis, linking it to tumorigenesis in these conditions (Fourouclas2008Methylation).

In inflammatory and autoimmune diseases, SOCS3 plays a crucial role by modulating immune responses. For instance, its deficiency enhances M1 macrophage polarization and exacerbates inflammatory responses, which are critical in conditions like arthritis and multiple sclerosis (Qin2012SOCS3). Additionally, elevated SOCS3 expression is associated with atopic dermatitis, indicating its involvement in inflammatory skin conditions (Ekelund2006Elevated).

Alterations in SOCS3 expression also affect cardiovascular health, as higher levels have been linked to an increased risk of acute myocardial infarction, underscoring its role in inflammatory processes within cardiovascular diseases (Meng2020High). These examples underscore the broad impact of SOCS3 on various pathological conditions, making it a significant focus for medical research and potential therapeutic interventions.

## Interactions
SOCS3 interacts with various proteins through its distinct structural domains, which facilitate both stable and transient protein-protein interactions crucial for its function in cytokine signaling pathways. The SH2 domain of SOCS3 binds to phosphorylated tyrosine residues on the gp130 component of the IL-6 receptor, as well as directly interacting with JAK2 kinase. This interaction is mediated by the kinase inhibitory region (KIR) of SOCS3, which blocks the substrate-binding groove on JAK2, thereby inhibiting its kinase activity (Kershaw2013SOCS3). 

Additionally, SOCS3's C-terminal SOCS box region interacts with elongin C, a component of the ubiquitin ligase complex. This interaction can lead to either the stabilization or proteasomal degradation of SOCS3, depending on its phosphorylation state. Phosphorylation at Tyr 204 and Tyr 221 disrupts the interaction with elongin C, promoting SOCS3 degradation (Haan2003Tyrosine).

SOCS3 also forms part of a larger multiprotein complex involving JAK2 and cytokine receptors, which enhances the specificity and efficacy of JAK signaling inhibition. This complex formation is critical for the targeted inhibition of cytokine signaling pathways mediated by specific receptors that interact with JAK2 and gp130 (Kershaw2013SOCS3).


## References


[1. (Bergamin2006Structural) Elisa Bergamin, Jinhua Wu, and Stevan R. Hubbard. Structural basis for phosphotyrosine recognition by suppressor of cytokine signaling-3. Structure, 14(8):1285â1292, August 2006. URL: http://dx.doi.org/10.1016/j.str.2006.06.011, doi:10.1016/j.str.2006.06.011. (69 citations) 10.1016/j.str.2006.06.011](https://doi.org/10.1016/j.str.2006.06.011)

[2. (Fourouclas2008Methylation) N. Fourouclas, J. Li, D. C. Gilby, P. J. Campbell, P. A. Beer, E. M. Boyd, A. C. Goodeve, D. Bareford, C. N. Harrison, J. T. Reilly, A. R. Green, and A. J. Bench. Methylation of the suppressor of cytokine signaling 3 gene (socs3) in myeloproliferative disorders. Haematologica, 93(11):1635â1644, September 2008. URL: http://dx.doi.org/10.3324/haematol.13043, doi:10.3324/haematol.13043. (113 citations) 10.3324/haematol.13043](https://doi.org/10.3324/haematol.13043)

[3. (Ying2010Loss) Mingzhen Ying, Dawei Li, Linjun Yang, Mei Wang, Ning Wang, Ying Chen, Miaoxia He, and Yajie Wang. Loss of socs3 expression is associated with an increased risk of recurrent disease in breast carcinoma. Journal of Cancer Research and Clinical Oncology, 136(10):1617â1626, February 2010. URL: http://dx.doi.org/10.1007/s00432-010-0819-6, doi:10.1007/s00432-010-0819-6. (45 citations) 10.1007/s00432-010-0819-6](https://doi.org/10.1007/s00432-010-0819-6)

[4. (White2011Suppressor) Gemma E. White, Andrew Cotterill, Mark R. Addley, Elizabeth J. Soilleux, and David R. Greaves. Suppressor of cytokine signalling protein socs3 expression is increased at sites of acute and chronic inflammation. Journal of Molecular Histology, 42(2):137â151, March 2011. URL: http://dx.doi.org/10.1007/s10735-011-9317-7, doi:10.1007/s10735-011-9317-7. (77 citations) 10.1007/s10735-011-9317-7](https://doi.org/10.1007/s10735-011-9317-7)

[5. (Haan2003Tyrosine) Serge Haan, Paul Ferguson, Ulrike Sommer, Meena Hiremath, Daniel W. McVicar, Peter C. Heinrich, James A. Johnston, and Nicholas A. Cacalano. Tyrosine phosphorylation disrupts elongin interaction and accelerates socs3 degradation. Journal of Biological Chemistry, 278(34):31972â31979, August 2003. URL: http://dx.doi.org/10.1074/jbc.m303170200, doi:10.1074/jbc.m303170200. (170 citations) 10.1074/jbc.m303170200](https://doi.org/10.1074/jbc.m303170200)

[6. (Babon2006The) Jeffrey J. Babon, Edward J. McManus, Shenggen Yao, David P. DeSouza, Lisa A. Mielke, Naomi S. Sprigg, Tracy A. Willson, Douglas J. Hilton, Nicos A. Nicola, Manuel Baca, Sandra E. Nicholson, and Raymond S. Norton. The structure of socs3 reveals the basis of the extended sh2 domain function and identifies an unstructured insertion that regulates stability. Molecular Cell, 22(2):205â216, April 2006. URL: http://dx.doi.org/10.1016/j.molcel.2006.03.024, doi:10.1016/j.molcel.2006.03.024. (197 citations) 10.1016/j.molcel.2006.03.024](https://doi.org/10.1016/j.molcel.2006.03.024)

[7. (Kershaw2013SOCS3) Nadia J Kershaw, James M Murphy, Nicholas P D Liau, Leila N Varghese, Artem Laktyushin, Eden L Whitlock, Isabelle S Lucet, Nicos A Nicola, and Jeffrey J Babon. Socs3 binds specific receptorâjak complexes to control cytokine signaling by direct kinase inhibition. Nature Structural &amp; Molecular Biology, 20(4):469â476, March 2013. URL: http://dx.doi.org/10.1038/nsmb.2519, doi:10.1038/nsmb.2519. (304 citations) 10.1038/nsmb.2519](https://doi.org/10.1038/nsmb.2519)

[8. (Chen2006Selective) Zhi Chen, Arian Laurence, Yuka Kanno, Margit Pacher-Zavisin, Bing-Mei Zhu, Cristina Tato, Akihiko Yoshimura, Lothar Hennighausen, and John J. OâShea. Selective regulatory function of socs3 in the formation of il-17-secreting t cells. Proceedings of the National Academy of Sciences, 103(21):8137â8142, May 2006. URL: http://dx.doi.org/10.1073/pnas.0600666103, doi:10.1073/pnas.0600666103. (519 citations) 10.1073/pnas.0600666103](https://doi.org/10.1073/pnas.0600666103)

[9. (Babon2008The) Jeffrey J. Babon, Jennifer K. Sabo, Alfreda Soetopo, Shenggen Yao, Michael F. Bailey, Jian-Guo Zhang, Nicos A. Nicola, and Raymond S. Norton. The socs box domain of socs3: structure and interaction with the elonginbc-cullin5 ubiquitin ligase. Journal of Molecular Biology, 381(4):928â940, September 2008. URL: http://dx.doi.org/10.1016/j.jmb.2008.06.038, doi:10.1016/j.jmb.2008.06.038. (126 citations) 10.1016/j.jmb.2008.06.038](https://doi.org/10.1016/j.jmb.2008.06.038)

[10. (Meng2020High) Heyu Meng, Xue Wang, Jianjun Ruan, Weiwei Chen, Fanbo Meng, and Ping Yang. High expression levels of the socs3 gene are associated with acute myocardial infarction. Genetic Testing and Molecular Biomarkers, 24(7):443â450, July 2020. URL: http://dx.doi.org/10.1089/gtmb.2020.0040, doi:10.1089/gtmb.2020.0040. (17 citations) 10.1089/gtmb.2020.0040](https://doi.org/10.1089/gtmb.2020.0040)

[11. (Qin2012SOCS3) Hongwei Qin, Andrew T. Holdbrooks, Yudong Liu, Stephanie L. Reynolds, Lora L. Yanagisawa, and Etty N. Benveniste. Socs3 deficiency promotes m1 macrophage polarization and inflammation. The Journal of Immunology, 189(7):3439â3448, October 2012. URL: http://dx.doi.org/10.4049/jimmunol.1201168, doi:10.4049/jimmunol.1201168. (325 citations) 10.4049/jimmunol.1201168](https://doi.org/10.4049/jimmunol.1201168)

[12. (Carow2014SOCS3) Berit Carow and Martin E. Rottenberg. Socs3, a major regulator of infection and inflammation. Frontiers in Immunology, 2014. URL: http://dx.doi.org/10.3389/fimmu.2014.00058, doi:10.3389/fimmu.2014.00058. (544 citations) 10.3389/fimmu.2014.00058](https://doi.org/10.3389/fimmu.2014.00058)

[13. (Ekelund2006Elevated) E. Ekelund, A. SÃ¤Ã¤f, M. Tengvall-Linder, E. Melen, J. Link, J. Barker, N.J. Reynolds, S.J. Meggitt, J. Kere, C.-F. Wahlgren, G. Pershagen, M. Wickman, M. NordenskjÃ¶ld, I. Kockum, and M. Bradley. Elevated expression and genetic association links the socs3 gene to atopic dermatitis. The American Journal of Human Genetics, 78(6):1060â1065, June 2006. URL: http://dx.doi.org/10.1086/504272, doi:10.1086/504272. (67 citations) 10.1086/504272](https://doi.org/10.1086/504272)

[14. (Babon2005Secondary) Jeffrey J. Babon, Shenggen Yao, David P. DeSouza, Christopher F. Harrison, Louis J. Fabri, Edvards Liepinsh, Sergio D. Scrofani, Manuel Baca, and Raymond S. Norton. Secondary structure assignment of mouse socs3 by nmr defines the domain boundaries and identifies an unstructured insertion in the sh2 domain. The FEBS Journal, 272(23):6120â6130, November 2005. URL: http://dx.doi.org/10.1111/j.1742-4658.2005.05010.x, doi:10.1111/j.1742-4658.2005.05010.x. (44 citations) 10.1111/j.1742-4658.2005.05010.x](https://doi.org/10.1111/j.1742-4658.2005.05010.x)